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Warfarin is an inexpensive and commonly used drug that is regularly 
prescribed in the public healthcare sector. Use of this drug is labour 
intensive, and patients in our setting undergo monthly international 
normalised ratio (INR) monitoring with regular dosing regimen 
adjustments.[1] Difficulties associated with warfarin use include 
frequent drug interactions, drug-food interactions, and life-threatening 
complications due to subtherapeutic or excessively elevated INRs. [2,3] 
Managing the patient on warfarin is complex, and with the added 
burden of complications increases the economic impact on the 
healthcare system and negatively affects patients’ quality of life.
Large pharmacoeconomic studies have been conducted in the 
USA and Europe to evaluate the costs involved when prescribing 
warfarin.[4] The relevance and applicability of these studies have 
become more apparent with the advent of the new or direct-acting 
oral anticoagulants (NOACs), which work by directly inhibiting 
thrombin or factor Xa. Warfarin inhibits the vitamin K-dependent 
synthesis of clotting factors II, VII, IX and X, as well as the regulatory 
factors protein C and protein S.[5] Warfarin use not only involves the 
direct costs of the drug and monthly INR monitoring, but additional 
costs in the form of supplementary hospital outpatient consultations, 
add-on bloods (full blood counts, renal and liver function tests), and 
sometimes the cost of inpatient care.
Wentworth Hospital (WWH), a public healthcare district hospital 
in Durban, South Africa (SA), has a dedicated outpatient warfarin 
clinic that is conducted every Friday. Unlike many other patients with 
chronic medical conditions who are seen 6-monthly when stable, 
patients on warfarin are seen at a maximum time interval of 1 month, 
and visits may occur weekly if the INR is found to be suboptimal.
Objectives
To evaluate the quality of care of patients on warfarin therapy 
presenting to an urban district hospital in KwaZulu-Natal Province, 
by assessing the financial and psychosocial burden of treatment.
Methods
This was a cross-sectional, observational, analytical study in which 
all patients who attended the warfarin clinic at WWH over a period 
of 4 weeks were interviewed to assess their quality of care. WWH is 
a busy urban district hospital in KwaZulu-Natal and the only district 
hospital in the south of eThekwini district. It has a catchment area 
with a population of ~333 740.[6] According to WWH statistics for the 
2016/17 financial year, 10 600 outpatients were seen per month and 
764 patients were admitted per month. An additional average of 989 
patients visited the emergency department on a monthly basis. For 
the data collection period July - August 2017, there were six medical 
officers and two interns working in the outpatient department. The 
number of patients seen was 7 334 for July and 7 697 for August, with 
the average medical officer seeing 51.4 patients per day.
The participants’ outpatient and inpatient files were retrospectively 
reviewed for the preceding 6-month period and all costs involved 
with each warfarin-related outpatient visit and inpatient stay were 
calculated. The maximum time for a follow-up appointment for these 
patients is 4 weeks, so the sample included all patients currently on 
warfarin therapy from the hospital. Patients attending the Friday 
clinic were included in the study, as well as patients admitted for 
complications arising from their warfarin use. Patients who were 
admitted after hours were also included in the study and their clinical 
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Conclusions. Warfarin still appears to be the most cost-effective drug in our setting, but it significantly affects patients’ quality of life. We 
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anticoagulants at a district hospital facility.
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files were retrieved from the admission ward. Patients presenting to 
the medical outpatient department for routine INR monitoring on any 
day but Friday as well as those with lost clinical files and those who 
had been on treatment for <3 months were excluded from the study. 
A patient’s file was deemed to be lost if it could not be found on more 
than two separate occasions.
The study consisted of three components: a structured patient 
interview, a 6-month retrospective outpatient file review, and an 
inpatient file review of any admissions. The patient interview was 
further subdivided into two sections. Section A was used to verify 
whether a patient had been admitted to hospital during the past 6 
months. The admission was reviewed to determine whether it was 
related to the patient’s warfarin use, the date of admission and the 
use of blood or blood products. Questions in section B assessed the 
quality of care, patient expenses and patients’ willingness to pay for 
alternatives. The questionnaire used in the interview was piloted at 
WWH and minor adjustments were made before use in the study. 
The piloted questionnaires were not included as part of the study 
population. The questionnaires were administered before each patient’s 
consultation on their clinic day. It was administered by the first author, 
who asked the questions in English or Afrikaans. We employed a 
nursing assistant who assisted us with asking the questions in isiZulu. 
All patient responses were filled in by the data collectors.
The outpatient file review was aimed at determining the 
demographics and clinical profile of the patients, ascertaining 
outpatient costs, and finding objective evidence of warfarin-related 
hospital admissions. In determining the outpatient costs, the 
following information was sought: number of monthly warfarin 
tablets prescribed, number of blood investigations (including INRs) 
performed, and number of outpatient and emergency room visits.
Evidence of admission was based on one of the following criteria: 
an inpatient number, evidence of a discharge summary, evidence of 
admission in the outpatient notes, and review of the admission ward 
register. Once admission was confirmed, the inpatient notes were 
retrieved and key data elements were extracted. The inpatient review 
was aimed at determining healthcare costs such as the number of 
days admitted, use of blood and blood products, medications and 
costs of investigations.
Conservatism was the fundamental principle in determining costs. 
If there was doubt, either a specific cost was excluded or the less 
expensive option was chosen. Drug costs were obtained from the SV 
35 Item Catalogue for the Provincial Pharmaceutical Supply Depot, 
date 1 June 2017. National Health Laboratory Service (NHLS) costs 
were obtained from the NHLS state price list for 2013. Blood and 
blood product costs were obtained from the South African National 
Blood Service state patient price list for 1 April 2016 - 31 March 
2017. Inpatient costs were extrapolated from WWH statistics for the 
2016/27 financial year, which estimate the cost of an inpatient day to 
be ZAR2 698. Outpatient consultation and emergency department 
costs were obtained from the 2017 hospital fees manual as there was 
no direct outpatient cost calculated by the hospital. These costs were 
calculated at the same value that a full-paying patient would pay, with 
the assumption made that this should cover 100% of all costs.
Statistical analysis
Data were extracted from the various source documents onto 
Microsoft Excel 2010 (Microsoft, USA) and imported in Stata version 
13 (StataCorp, USA) for analysis. The costing data were found to 
be skewed and medians with interquartile ranges (IQRs) were used 
to interpret the data, with mean values (standard error of the mean 
(SEM)) used to determine individual and total costs. Statistical 
analysis was conducted with the assistance of a statistician from the 
College of Health Sciences, University of KwaZulu-Natal. The study 
population was divided into male and female and above and below 
60 years of age. The age 60 was chosen to separate the population 
into young and old, with a patient aged ≥60 years being classified as 
elderly. A p-value <0.05 was considered significant.
Quality of care data were converted from categorical to numerical 
data. Means and medians were used to interpret data with standard 
deviations (SDs) and IQRs used to determine data spread.
Ethical considerations
Permission to conduct this study was obtained from the Biomedical 
Research Ethics Committee, University of KwaZulu-Natal (ref. no. 
BE364/17), the KwaZulu-Natal Department of Health’s ethical review 
board (ref. no. KZ_2017RP4_664) and the CEO of WWH. Written 
informed consent was individually obtained from every patient 
included in the study.
Results
A total of 128 patients were eligible for the study, of whom 18 (14.1%) 
were excluded, giving a final number of 110 participants. A total of 
135 patients were booked for the clinics for the study period. Of 
the patients excluded, 9 had been on treatment for <3 months and 
9 patients’ files were not found.
Table 1 illustrates the relationship between age and a number of 
variables measured.
There was a statistically significant difference between respondents 
under and over 60 years of age with regard to atrial fibrillation (AF), 
prosthetic heart valves and hypertension. The prevalences of AF and 
hypertension were higher in patients aged >60 years, while prosthetic 
heart valves were more common in patients aged <60 years.
The total cost of all expenses related to warfarin per patient per 
month (pppm) over a 6-month period was calculated as ZAR394.98 
and is tabulated with other costs in Table 2.
The total cost attributed to warfarin for all patients over a 6-month 
period was ZAR260  628.83, with the different cost components 
illustrated in Fig. 1.
Warfarin 5 mg tablet costs, INR costs, costs of additional blood 
investigations and outpatient visits amounted to a total outpatient 
cost of ZAR204 014.33. Admissions resulted in a total inpatient cost 
of ZAR56  614.50. The total number of outpatient INRs performed 
amounted to 741, with an average of 6.7 INRs per patient over 6 
months. Urea, creatinine and electrolytes was the most prevalent 
additional investigation done (n=34), followed by full blood counts 
(n=28), liver function tests (n=19), glycated haemoglobin (n=12), 
lipograms (n=10), thyroid function tests (n=6), prostate-specific 
antigen tests (n=5) and calcium, magnesium and phosphate (n=4).
A total of 717 chronic outpatient, 6 accident and emergency and 
10 acute outpatient visits were directly related to warfarin use. These 
visits consisted of routine INR monitoring or complications of an 
elevated or subtherapeutic INR. Three patients who fulfilled our 
inclusion criteria were admitted to hospital. Three inpatients were 
excluded because they had been on treatment for <3 months or their 
files were missing. One patient was admitted for a subtherapeutic 
INR and 2 were admitted for warfarin toxicity with an elevated 
INR. One patient was treated for warfarin toxicity in the emergency 
department and discharged within 24 hours. The mean inpatient 
stay for the 2.7% of patients who required admission for a warfarin-
related complication over the study period was 6.3 days. Three 
patients required admission for non-warfarin-related indications, 
and the costs of these admissions were not included in the costs of 
warfarin use. Table 3 lists patients’ satisfaction with the quality of 
care received.
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Table 1. Relationship between age and variables measured (N=110)
 
Age (years)
Total (N)  p-value <60 (N=53), n (%) >60 (N=57), n (%)
Sex
Male 24 (45.3) 26 (45.6) 50 0.9
Female 29 (54.7) 31 (54.4) 60
Indication
AF 9 (17.0) 33 (57.9) 42 <0.001
Prosthetic heart valve 33 (62.3) 14 (24.6) 47 <0.001
DVT 5 (9.4) 4 (7.0) 9 0.6
PE 3 (5.7) 1 (1.8) 4 0.4
Other 4 (7.5) 5 (8.8) 9 0.8
Comorbidities
Diabetes 6 (11.3) 17 (29.8) 23 0.02
Prosthetic heart valve with comorbid AF 9 (17.0) 7 (12.3) 16 0.5
Hypertension 16 (30.2) 40 (70.2) 56 <0.001
Dyslipidaemia 4 (7.5) 14 (24.6) 18 0.02
IHD 1 (1.9) 10 (17.5) 11 0.009
Cardiac failure 3 (5.7) 15 (26.3) 18 0.003
COPD 1 (1.9) 3 (5.3) 4 0.6
Asthma 3 (5.7) 3 (5.3) 6 0.9
Other 24 (45.3) 19 (33.3) 43 0.2
Comorbidities, N
0 17 (32.1) 6 (10.5) 23 0.005
1 14 (26.4) 12 (21.1) 26 0.508
2 17 (32.1) 15 (26.3) 32 0.506
≥3 5 (9.4) 24 (42.1) 29 <0.001
Time spent at hospital (hours)
0 - <5 16 (30.2) 13 (22.8) 29 0.38
≥5 - <6 hours 14 (26.4) 32 (56.1) 46 0.002
≥6 23 (43.4) 12 (21.1) 35 0.012
Willingness to pay
Not willing to pay 9 (17.0) 8 (14.0) 17 0.669
ZAR0 - 49 16 (30.2) 28 (49.1) 44 0.04
ZAR50 - 99 17 (32.1) 15 (26.3) 32 0.506
ZAR100 - 199 8 (15.1) 3 (5.3) 11 0.086
≥ZAR200 3 (5.7) 3 (5.3) 6 0.927
AF = atrial fibrillation; DVT = deep-vein thrombosis; PE = pulmonary embolism; IHD = ischaemic heart disease; COPD = chronic obstructive pulmonary disease.
Table 2. Costs of prescribing warfarin
  Patients (N) ZAR IQR/SEM
Total costs pppm
Median (IQR) 110 295.05 283.42 - 333.17
Mean (SEM) 110 394.89 53.03
Non-valvular AF costs pppm
Median (IQR) 42 294.40 283.85 - 345.10
Mean (SEM) 42 430.54 116.14
Other indications pppm
Median (IQR) 68 296.13 279.97 - 330.2
Mean (SEM) 68 372.87 47.69
Inpatient and emergency department cost pp 6 mo
Median (IQR) 4 12 141.00 5 385.13 - 22 922.13
Mean (SEM) 4 14 153.63 5 866.00
Outpatient cost pp 6 mo
Median (IQR) 110 1 764.80 1 690.83 - 1 982.22
Mean (SEM) 110 1 854.68 46.37
IQR = interquartile range; SEM = standard error of the mean; AF = atrial fibrillation; pppm = per patient per month; pp 6 mo = total cost per patient during the 6-month study period.
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The quality of care analysis also revealed that 80.0% of participants 
agreed or strongly agreed that they were satisfied with the care 
they received, 69.1% agreed or strongly agreed that monthly INR 
monitoring frustrated them, and 74.5% agreed or strongly agreed that 
they wished they did not have to take warfarin.
The monthly mean (SEM) transportation cost per patient was 
calculated at ZAR57.20 (6.89). Of the patients, 84.5% would be 
willing to pay for a drug that required less monitoring and fewer 
clinic visits; however, 47.3% of patients willing to pay could only 
afford ZAR0 - 50 per month.
Discussion
Main findings
From the main study findings, it was concluded that warfarin affects 
the quality of life of our patient population to the extent that many 
patients would be willing to pay for an alternative drug. In addition, 
we found that warfarin is a cost-effective treatment option in our 
setting. Outpatient consultations, admission costs and expenses 
incurred by patients with non-valvular AF accounted for the largest 
proportion of expenses.
Other findings
The majority of patients were satisfied with the overall quality of 
care they received at WWH. Many commented that having a specific 
clinic day and a dedicated warfarin clinic greatly contributed to 
this. Unfortunately, this does not offset the effect that monthly 
consultations and blood investigations has on the patient population, 
with over two-thirds of the patients reporting that they wished they 
did not have to take this drug. In addition, the majority of patients 
spent 5 - 6 hours at hospital awaiting blood results and medication, 
and spent ZAR57.20 on getting to and from the hospital every month. 
In a population that consists mostly of the elderly, pensioners and the 
unemployed, this transportation cost is considered to be excessive. 
Individuals who receive a government pension of ZAR1 600 per 
month spend on average ZAR686.4 per year on transportation.[7]
In a health-related quality of life analysis from the RE-LY trial, 
Monz et al.[8] compared the quality of life of patients on dabigatran 
with those on warfarin. The visual analogue scale of the EQ-5D 
questionnaire (range 0 - 100, with 100 being best imaginable health) 
among others was used to determine this and found that after 
12  months of treatment with warfarin the mean score was 74.0 
(range 71.6 - 76.5).[9] These results contrast with our results, and the 
reasons for this difference are thought to be multifactorial. We believe 
that the underlying frustrations of our patients can be attributed to 
the pain of monthly venepunctures, long waiting times and additional 
financial burdens. With these frustrations in mind, we asked our 
patients if they would be willing to pay for a drug that requires fewer 
clinic visits and less monitoring, to which a substantial majority agreed. 
This is significant in view of our study population’s already poor 
socioeconomic circumstances. These circumstances are highlighted by 
the largest proportion of patients stating that they would only be able 
to afford ZAR0 - 50 per month for an alternative drug.
Our data collection showed that AF is a disease of the elderly and 
that prosthetic heart valves are more prevalent in individuals aged 
<60 years. The decision to divide the population into over and under 
60 years was based on data from the Framingham Study, which 
suggested that the risk of stroke from AF increased significantly 
across the decades after 50 - 59 years of age.[10] We found a statistically 
significant prevalence of hypertension in participants aged >60 years, 
which can be linked to the increased incidence of AF in the same 
age group. This result is comparable to other studies that emphasise 
the need for early cardiovascular risk factor control and prevention, 
as an increase in age and hypertensive heart disease are major risk 
factors for the development of AF.[11] The demographics and risk 
factor profile in our study are similar to an SA study by Sonuga et 
al.[12] They found hypertension to be the commonest comorbidity, 
and the patient population consisted of more females than males. 
A notable difference is that the commonest indication for warfarin 
was AF and not prosthetic heart valves as in our study. A reason for 
this may be that many patients had valve replacements at WWH, as 
cardiothoracic surgery used to be based there.[12]
We designed our costing model to include all costs involved 
when prescribing warfarin, such as additional blood investigations 
performed at the monthly clinic visit. From a costing perspective, 
we found two broad groups as illustrated by the non-linear spread of 
data: those requiring admission and those not requiring admission. 
We found no significant difference between the total median cost 
pppm, the median cost of non-valvular AF (NVAF) pppm and other 
indications for warfarin pppm. AF appears to be a main driver of 
costs, with significant differences between the average cost of NVAF 
pppm in comparison with the average cost of other indications. These 
differences in the average costs between AF and non-AF patients can 
be attributed to the AF patients’ admission costs and additional blood 
investigations. This finding is in keeping with an economic analysis 
conducted in the UK, where admission fees contributed to 50% of 
total AF costs.[13]
Admissions
ZAR56 614.50, 
22%
Warfarin 5 mg tablets 
ZAR13 140.30, 
5%
INR 
ZAR34 960.38, 
13% Additional blood 
investigations 
ZAR17 257.66, 
7%
Outpatient visits
ZAR138 656.00, 
53%
Fig. 1. Total cost of warfarin. (INR = international normalised ratio.)
Table 3. Quality of care (N=110)
Mean (SD) Median IQR
Treatment satisfaction 3.89 (1.03) 4 4 - 5
I am often frustrated with having to come to the hospital every month for blood tests 3.75 (1.22) 4 2 - 5
I sometimes wish that I did not have to take warfarin 4 (1.18) 4 3 - 5
Willing to pay for an alternative drug 3.82 (0.84) 4 2 - 4
1 = strongly disagree, 2 = disagree, 3 = neutral, 4 = agree, 5 = strongly agree.
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After determining the costs of warfarin, we contacted the manu-
facturers of dabigatran, Boehringer-Ingelheim South Africa, and 
rivaroxaban, Bayer South Africa, in an attempt to determine what 
the cost price of these drugs would be in the state sector. Depending 
on factors such as volume sold, Boehringer-Ingelheim estimated that 
dabigatran would cost the National Department of Health between 
ZAR673.85 and ZAR700.80 for a month’s supply. Bayer estimated 
that the cost of rivaroxaban would be between 50% and 75% of the 
current single exit price. The medicine price registry lists the maximum 
single exit price of rivaroxaban 20 mg at ZAR1 091.92 (including VAT 
and dispensing fees) for a month’s supply.[14] Using this figure, the 
cost of rivaroxaban tablets alone would be between ZAR545.96 and 
ZAR818.94 per patient per month. These costs exclude event costs such 
as admissions, blood products and additional blood investigations.
The ROCKET-AF, ARISTOTLE and RE-LY studies found the 
NOACs to be non-inferior to and in some cases superior to warfarin. [15-
17] Dabigatran 150 mg twice daily has a stroke or systemic embolism 
rate of 1.11% per year for patients with NVAF compared with 1.69% 
per year for patients on dose-adjusted warfarin (p<0.001). The rates 
of major bleeding for dabigatran 150 mg and dose-adjusted warfarin 
appear to be similar, but there is a significantly decreased risk of 
life-threatening intracranial bleeds with dabigatran 110 mg (0.12%; 
p<0.001) and 150 mg (0.10%; p<0.001) in comparison with warfarin 
(0.38%).[17] Rivaroxaban showed similar results, with a significant 
reduction in fatal bleeds in comparison with warfarin (0.2% v. 0.5%; 
p=0.003).[15] Rivaroxaban also appears to be more effective than 
aspirin in the prevention of secondary cardiovascular events.[18]
As a result of these findings, pharmacoeconomic studies were 
conducted using Markov decision models in an attempt to evaluate 
the cost-effectiveness of the NOACs. These studies found that the 
NOACs are a cost-effective alternative when compared with dose-
adjusted warfarin.[4,19,20] Bergh et al.[21] conducted a similar cost-
effectiveness analysis in the SA private sector and came to the same 
conclusion as the international studies.
We believe that our results differ from the international literature 
because of our setting and the availability of generic medication. 
Patients at WWH are seen by medical officers at district hospital 
level, which in combination with the relatively low cost of warfarin 
5 mg tablets significantly decreases costs.
Study limitations
Assessment of cost-effectiveness was challenging owing to difficulties 
in determining outpatient consultation costs, missing files and a 
paper filing system. Some admitted patients were excluded because 
files were missing, and if these costs were included they could 
add a substantial amount to the total costs per patient per month. 
As this was a cross-sectional study, we were only able to give a 
6-month snapshot of the various social and economic factors 
influencing patients on warfarin, which makes it difficult to draw 
accurate conclusions. We believe that a longer study time frame 
would influence both cost-effectiveness and quality of care data. 
Unfortunately, a retrospective review of more than 6 months will be 
difficult owing to the challenges associated with a paper filing system, 
missing files and recall bias.
Other study limitations include using only one site for data 
collection and using subjective measures to gauge socioeconomic 
status and income.
Conclusions
We found that warfarin has an adverse effect on our patients’ 
quality of life, but it is still the most cost-effective anticoagulant in 
our setting. The NOACs will only be a cost-effective alternative in 
a district health setting if the current estimated public sector drug 
prices for both rivaroxaban and dabigatran are approximately halved. 
One cannot ignore the pharmacological benefits and convenience 
of the NOACs, together with the psychosocial disadvantages of 
warfarin. On this basis we suggest a prospective head-to-head trial 
that compares both cost-effectiveness and quality of life of patients 
on warfarin and NOACs at a district health level.
Introduction of these new agents has the potential to improve 
quality of care for all patients on anticoagulation treatment. For 
those still on warfarin it will decrease waiting times and allow for 
more doctor/patient contact, while those on a NOAC will need fewer 
clinic visits and blood investigations. This will ultimately decrease the 
congestion at district hospitals.
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